Dexmedetomidine for Continuous Sedation
A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit
Sponsor: Orion Corporation, Orion Pharma
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Orion Corporation, Orion Pharma
Other Conscious Sedation trials with similar outcome
This PHASE3 trial investigates Conscious Sedation and is currently terminated or withdrawn. Orion Corporation, Orion Pharma leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Orion Corporation, Orion Pharma
For direct contact, visit the study record on ClinicalTrials.gov .